D'Hondt V - Search Results

1

[Combining surgery and medical treatments for ovarian cancer: Is there an optimal strategy?].

Thomas QD, Quesada S, D'Hondt V, Belaroussi I, Laas E, Classe JM, Fabbro M, Colombo PE, Fiteni F. Thomas QD, et al. Bull Cancer. 2022 Feb;109(2):197-215. doi: 10.1016/j.bulcan.2021.11.013. Epub 2022 Jan 10. Bull Cancer. 2022. PMID: 35027164 Review. French.

2

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

Mazzeo F, Berlière M, Kerger J, Squifflet J, Duck L, D'Hondt V, Humblet Y, Donnez J, Machiels JP. Mazzeo F, et al. Gynecol Oncol. 2003 Jul;90(1):163-9. doi: 10.1016/s0090-8258(03)00249-x. Gynecol Oncol. 2003. PMID: 12821358

3

Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.

D'Hondt V, Goffin F, Roca L, Dresse D, Leroy C, Kerger J, Cordier L, de Forges H, Veys I, Liberale G. D'Hondt V, et al. Int J Gynecol Cancer. 2016 Jun;26(5):912-7. doi: 10.1097/IGC.0000000000000696. Int J Gynecol Cancer. 2016. PMID: 27051055 Free article. Clinical Trial.

4

Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute.

Kurtz JE, D'Hondt V, Lécuru F, Lhommé C. Kurtz JE, et al. Bull Cancer. 2017 May;104 Suppl 1:S39-S42. doi: 10.1016/S0007-4551(17)30161-3. Bull Cancer. 2017. PMID: 28625314 French.

5

Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.

Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C. Fabbro M, et al. Cancers (Basel). 2020 Aug 5;12(8):2184. doi: 10.3390/cancers12082184. Cancers (Basel). 2020. PMID: 32764409 Free PMC article.

6

Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients.

Aptecar L, Fiteni F, Jarlier M, Delaine S, Guillerme V, Jacot W, D'Hondt V. Aptecar L, et al. Breast Cancer Res Treat. 2021 Apr;186(3):705-713. doi: 10.1007/s10549-020-06062-x. Epub 2021 Jan 15. Breast Cancer Res Treat. 2021. PMID: 33452553

7

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.

Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Pouderoux S, Champoiral P, Janiszewski C, Nicklès I. Fabbro M, et al. Among authors: d hondt v. Cancer Rep (Hoboken). 2023 Jan;6(1):e1732. doi: 10.1002/cnr2.1732. Epub 2022 Oct 27. Cancer Rep (Hoboken). 2023. PMID: 36302744 Free PMC article.

8

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer.

Vendrell JA, Ban IO, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo PE, Legouffe E, D'Hondt V, Fabbro M, Solassol J. Vendrell JA, et al. Among authors: d hondt v. Int J Mol Sci. 2023 Sep 16;24(18):14181. doi: 10.3390/ijms241814181. Int J Mol Sci. 2023. PMID: 37762485 Free PMC article.

9

[Has the time arrived for gene expression use at the bedside?].

D'Hondt V, Piccart M, Sotiriou C. D'Hondt V, et al. Bull Cancer. 2008 Mar;95(3):336-43. doi: 10.1684/bdc.2008.0593. Bull Cancer. 2008. PMID: 18390414 Free article. Review. French.

10

First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions.

Metzger-Filho O, Moulin C, D'Hondt V. Metzger-Filho O, et al. Curr Opin Oncol. 2010 Sep;22(5):513-20. doi: 10.1097/CCO.0b013e32833ae99c. Curr Opin Oncol. 2010. PMID: 20485166 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page